Johnson & Johnson http://www.alacrastore.com/company-snapshot/Johnson_Johnson-1009082 Saturday, July 05, 2008 9:29:36 PM 1009082 Johnson & Johnson en AlacraStore RSS Builder 1.0 30 http://www.alacrastore.com/storecontent/newstex/MW-0001-26400332newstex/MW-0001-26400332xml LONDON, UNITED KINGDOM, Jul. #, #### (Marketwire delivered by Newstex) -- LONDON, UNITED KINGDOM -- (MARKET WIRE) -- ##/##/## -- Reportlinker.com announces that a new market research report related to the Feminine hygiene industry...130000001300400013004001040000000400700004007005040160000401601304010000040100017/2/2008 2:08:25 PM1800000018020000180220001801500019000000190010001900200019002004190020091900201319002007190020121900201019002018MarketwireMW-0001-26400332JOHNSON & JOHNSONKIMBERLY CLARK CORPJNJKMBNewsNewstexUS - One Equity Partners LLC, a unit of JPMorgan Chase & Co, planned to acquire the Professional Wound Care business of Ethicon Inc, a manufacturer of suturess and related wound closure devices, from Johnson & Johnson Inc, in a leveraged buyout transaction. Terms were not disclosed. The transaction was subject to customary closing conditions and regulatory approvals. The transaction was to include D and manufacturing facility located in Gargrave, England.7/2/2008 1:13:27 PM68285K29797W46625H478160One Equity Partners LLCEthicon Inc-Professional Wound Care BusinessJPMorgan Chase & CoJohnson & Johnson Inchttp://www.alacrastore.com/storecontent/Thomson_M%26A/One_Equity_Partners_LLC_acquires_Ethicon_Inc_Professional_Wound_from_Johnson_Johnson_Inc_through_a_leveraged_buyout-1992445020sdc/19924450201992445020Copyright © 2008, Thomson Financial, All Rights ReservedInvestment & Commodity Firms,Dealers,ExchangesUnited StatesInvestors, nec6799NYNew YorkSubsidiary6799:Investors, nec6021:National commercial banks6022:State banks,member fed reserve6141:Personal credit institutions6211:Security brokers, dealers, and flotation companies6221:Commodity contracts brokers and dealers6282:Investment advice6289:Security and commodity services, nec6712:Offices of bank holding companies6799:Investors, necMorgan Lewis & BockiusMeasuring, Medical, Photo Equipment; ClocksUnited StatesOrthopedic, prosthetic, and surgical supplies3842NJNew JerseySubsidiary760397002Pvd finl svcsMnfr,whl med equip,prodUnspecifiedAssets1026441001Jul 2 20080.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.00000270.000000.000000.000000.000000.000000.000000.000000.000000.0000031 Dec 0731 Dec 0731 Dec 0631 Dec 0531 Dec 0431 Dec 031.000001.000002.000003.000004.000005.000006.000007.000008.000009.00000One Equity Partners LLC,located in New York, New York,is a private equity firminvesting in industriesincluding defense, chemicals,healthcare, technology andmanufacturing. It has officesin Chicago and Germany. Thecompany was founded in 2001.One Equity Partners LLC, located in New York, New York, is aprivate equity firm investing in industries includingdefense, chemicals, healthcare, technology andmanufacturing. It has offices in Chicago and Germany. Thecompany was founded in 2001.One Equity Partners LLC, located in New York, New York, is a private equity firm investing in industries including defense, chemicals, healthcare, technology and manufacturing. It has offices in Chicago and Germany. The company was founded in 2001.1.000002.000003.000004.000005.000006.000007.000008.000009.0000010.0000011.0000012.00000Professional Wound Carebusiness of Ethicon Inccontains such brands asPROMOGRAN Matrix WoundDressing, TIELLE HydropolymerDressing and REGRANEX(becaplermin) Gel 0.01%, aprescription treatment forlower extremity diabeticulcers, as well as a portfolioof general wound careproducts.Professional Wound Care business of Ethicon Inc containssuch brands as PROMOGRAN Matrix Wound Dressing, TIELLEHydropolymer Dressing and REGRANEX (becaplermin) Gel 0.01%,a prescription treatment for lower extremity diabeticulcers, as well as a portfolio of general wound careproducts.Professional Wound Care business of Ethicon Inc contains such brands as PROMOGRAN Matrix Wound Dressing, TIELLE Hydropolymer Dressing and REGRANEX (becaplermin) Gel 0.01%, a prescription treatment for lower extremity diabetic ulcers, as well as a portfolio of general wound care products.0.000000.000000.000000.00000N01 Jul 08Tue, 01 Jul 2008 00:00:00 ESTDate Announced: 07/01/2008Date Effective:Acq. of AssetsFriendly0.000000.000000.000000.000000.000000.00000Price/Share0.0000000.000000.0000000.000000.000000.000000.000000.000000.0000000.00000N0.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.00000100.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000001.000002.000003.000004.000005.000006.000007.000008.000009.0000010.0000011.0000012.0000013.0000014.0000015.0000016.0000017.00000US - One Equity Partners LLC,a unit of JPMorgan Chase & Co,planned to acquire theProfessional Wound Carebusiness of Ethicon Inc, amanufacturer of suturess andrelated wound closure devices,from Johnson & Johnson Inc, ina leveraged buyouttransaction. Terms were notdisclosed. The transaction wassubject to customary closingconditions and regulatoryapprovals. The transaction wasto include D and manufacturingfacility located in Gargrave,England.US - One Equity Partners LLC, a unit of JPMorgan Chase & Co, planned to acquire the Professional Wound Care business of Ethicon Inc, a manufacturer of suturess and related wound closure devices, from Johnson & Johnson Inc, in a leveraged buyout transaction. Terms were not disclosed. The transaction was subject to customary closing conditions and regulatory approvals. The transaction was to include D and manufacturing facility located in Gargrave, England.US - One Equity Partners LLC, a unit of JPMorgan Chase & Co, planned to acquire theProfessional Wound Care business of Ethicon Inc, a manufacturer of suturess and relatedwound closure devices, from Johnson & Johnson Inc, in a leveraged buyout transaction.Terms were not disclosed. The transaction was subject to customary closing conditions andregulatory approvals. The transaction was to include D and manufacturing facility locatedin Gargrave, England.US - One Equity Partners LLC, a unit of JPMorgan Chase & Co, planned to acquire the Professional Wound Care business of Ethicon Inc, a manufacturer of suturess and related wound closure devices, fromJohnson & Johnson Inc, in a leveraged buyout transaction. Terms were not disclosed. The transaction was subject to customary closing conditions and regulatory approvals. The transaction was to includeD and manufacturing facility located in Gargrave, England.US - One Equity Partners LLC, a unit of JPMorgan Chase & Co, planned to acquire the Professional Wound Care business of Ethicon Inc, amanufacturer of suturess and related wound closure devices, from Johnson & Johnson Inc, in a leveraged buyout transaction. Terms were notdisclosed. The transaction was subject to customary closing conditions and regulatory approvals. The transaction was to include D andmanufacturing facility located in Gargrave, England.Pending0.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.00000270.000000.000000.000000.000000.00000270.000000.000000.000000.000000.000000.000000.00000Status:PendingUS-999.00000np0.00000-999.00000np0.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000003841:Surgical and medical instruments and apparatus3842:Orthopedic, prosthetic, and surgical supplies1183005New YorkUnited States6021New YorkPublicJPM2297:Nonwoven fabrics2676:Sanitary paper products2833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations2836:Biological products, except diagnostic substances2844:Perfumes, cosmetics, and other toilet preparations3841:Surgical and medical instruments and apparatus3843:Dental equipment and supplies3851:Ophthalmic goods5047:Medical, dental, and hospital equipment & supplies5048:Ophthalmic goods5122:Drugs, drug proprietaries, and druggists' sundries6719:Offices of holding companies, nec8731:Commercial physical and biological research3275001New YorkUnited States2834New JerseyPublicJNJ0.000000.000000.000000.00000Deal InformationThomson Financial Mergers & Acquisitionshttp://www.alacrastore.com/storecontent/fitch/425183_pr_framefitch/425183_pr_framehtmlFitch Ratings is a leading global rating agency committed to providing the world's credit markets with independent, timely and prospective credit opinions. Built on a foundation of organic growth and strategic acquisitions, Fitch Ratings has grown rapidly during the past decade gaining market presence throughout the world and across all fixed income markets.Johnson & Johnson808438847/2/2008 11:29:19 AM01030000010317000104000085Press ReleaseJNJ425183_pr_frameCredit & Investment ResearchFitchResearchSWEDEN - Johnson & Johnson Nordic AB, a wholly-owned unit of Johnson & Johnson Inc, acquired Amic AB, a Uppsala-based manufacturer of biological products.6/20/2008 11:56:09 AM01334T51349W47816051349WJohnson & Johnson Nordic ABAmic ABJohnson & Johnson IncAmic ABhttp://www.alacrastore.com/storecontent/Thomson_M%26A/Johnson_Johnson_Nordic_AB_acquires_Amic_AB-1988489040sdc/19884890401988489040Copyright © 2008, Thomson Financial, All Rights ReservedBusiness ServicesSwedenManagement consulting services8742FFForeignSubsidiary7319:Advertising, nec8742:Management consulting services2297:Nonwoven fabrics2676:Sanitary paper products2833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations2836:Biological products, except diagnostic substances2844:Perfumes, cosmetics, and other toilet preparations3841:Surgical and medical instruments and apparatus3843:Dental equipment and supplies3851:Ophthalmic goods5047:Medical, dental, and hospital equipment & supplies5048:Ophthalmic goods5122:Drugs, drug proprietaries, and druggists' sundries6719:Offices of holding companies, nec8731:Commercial physical and biological researchMeasuring, Medical, Photo Equipment; ClocksSwedenElectromedical and electrotherapeutic apparatus3845FFForeignPrivate1023783001Mnfr,whl med equip,prodMnfr biological prodUnspecifiedAssets572412001Jun 20 20080.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000001.000002.000003.00000Johnson & Johnson Nordic AB,located in Sollentuna, Sweden,provides marketing services.Johnson & Johnson Nordic AB, located in Sollentuna, Sweden,provides marketing services.Johnson & Johnson Nordic AB, located in Sollentuna, Sweden, provides marketing services.1.000002.000003.000004.000005.000006.000007.000008.00000Amic AB, located in Uppsala,Sweden, manufacturesreplicated micro-mechanical,micro-optical, andmicro-fluidic componentsutilizing lithography processand laser techniques. Thecompany was founded in 1998.Amic AB, located in Uppsala, Sweden, manufactures replicatedmicro-mechanical, micro-optical, and micro-fluidiccomponents utilizing lithography process and lasertechniques. The company was founded in 1998.Amic AB, located in Uppsala, Sweden, manufactures replicated micro-mechanical, micro-optical, and micro-fluidic components utilizing lithography process and laser techniques. The company was founded in 1998.0.000000.000000.000000.00000Y18 Jun 08Wed, 18 Jun 2008 00:00:00 ESTDate Announced: 06/18/200818 Jun 08Date Effective: 06/18/200818 Jun 08Acq. of AssetsFriendly0.000000.000000.000000.000000.000000.00000Price/Share0.0000000.000000.0000000.00000100.00000100.000000.000000.000000.0000000.00000N0.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.00000100.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000001.000002.000003.000004.000005.000006.00000SWEDEN - Johnson & JohnsonNordic AB, a wholly-owned unitof Johnson & Johnson Inc,acquired Amic AB, aUppsala-based manufacturer ofbiological products.SWEDEN - Johnson & Johnson Nordic AB, a wholly-owned unit of Johnson & Johnson Inc, acquired Amic AB, a Uppsala-based manufacturer of biological products.SWEDEN - Johnson & Johnson Nordic AB, a wholly-owned unit of Johnson & Johnson Inc,acquired Amic AB, a Uppsala-based manufacturer of biological products.SWEDEN - Johnson & Johnson Nordic AB, a wholly-owned unit of Johnson & Johnson Inc, acquired Amic AB, a Uppsala-based manufacturer of biological products.SWEDEN - Johnson & Johnson Nordic AB, a wholly-owned unit of Johnson & Johnson Inc, acquired Amic AB, a Uppsala-based manufacturer ofbiological products.Completed0.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.00000Status:Completed-999.00000np0.00000-999.00000np0.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000002836:Biological products, except diagnostic substances3845:Electromedical and electrotherapeutic apparatus3275001New YorkUnited States2834New JerseyPublicJNJ2836:Biological products, except diagnostic substances3845:Electromedical and electrotherapeutic apparatus572412001Sweden3845ForeignPrivate0.000000.000000.000000.00000Deal InformationThomson Financial Mergers & Acquisitionshttp://www.alacrastore.com/storecontent/fitch/424279_pr_framefitch/424279_pr_framehtmlFitch Ratings is a leading global rating agency committed to providing the world's credit markets with independent, timely and prospective credit opinions. Built on a foundation of organic growth and strategic acquisitions, Fitch Ratings has grown rapidly during the past decade gaining market presence throughout the world and across all fixed income markets.Johnson & Johnson808438846/19/2008 2:08:37 PM01030000010317000104000085Press ReleaseJNJ424279_pr_frameCredit & Investment ResearchFitchResearchhttp://www.alacrastore.com/storecontent/spcred/654908spcred/654908normThe latest News from S&Pglobalstructured6/19/2008 10:37:23 AM100News654908United StatesPharmaceuticalsAsiaEurope, Middle East, AfricaUnited StatesGlobal IssuersStructured FinanceCorporationsAsset-Backed SecuritiesConsumer ProductsHealth CareNewsOn June 19, 2008, Standard&Poor's Ratings Services assigned its 'AAA' rating to New Brunswick, N.J.-based Johnson&Johnson's notes which are being offered in two tranches: $900 million at 5.15%, maturing July 15, 2018, and $700 million at 5.85%, maturing July 15, 2038. These notes are being issued via a supplemental prospectus to a March 2008 WKSI registration. The corporate credit rating on Johnson&Johnson (J&J) is 'AAA', with a stable outlook. The rating continues to reflect J&J's leading market positions in a vast array of health care markets, long and successful acquisition experience, and steady ability to generate cash well in excess of internal needs. (For the latest complete corporate credit rating rationale, see Standard&USA47816047816D47816E47816F47816G35202010 352020 3520 35Johnson&Johnson101256ASIAEUROMIDAFRUSAJNJNEWSGLOBISSSTRUCCORPABSConsumerHealthCredit & Investment ResearchS&P Credit Researchhttp://www.alacrastore.com/storecontent/spcred/654909spcred/654909normThe latest Research Update from S&Pglobalstructured6/19/2008 10:37:23 AM175Research Update654909United StatesPharmaceuticalsAsiaEurope, Middle East, AfricaUnited StatesGlobal IssuersStructured FinanceCorporationsAsset-Backed SecuritiesConsumer ProductsHealth CareResearch UpdateOn June 19, 2008, Standard&Poor's Ratings Services assigned its 'AAA' rating to New Brunswick, N.J.-based Johnson&Johnson's notes which are being offered in two tranches: $900 million at 5.15%, maturing July 15, 2018, and $700 million at 5.85%, maturing July 15, 2038. These notes are being issued via a supplemental prospectus to a March 2008 WKSI registration. The corporate credit rating on Johnson&Johnson (J&J) is 'AAA', with a stable outlook. The rating continues to reflect J&J's leading market positions in a vast array of health care markets, long and successful acquisition experience, and steady ability to generate cash well in excess of internal needs. (For the latest complete corporate credit rating rationale, see Standard&USA47816047816D47816E47816F47816G35202010 352020 3520 35Johnson&Johnson101256ASIAEUROMIDAFRUSAJNJRESUPDGLOBISSSTRUCCORPABSConsumerHealthCredit & Investment ResearchS&P Credit Researchhttp://www.alacrastore.com/storecontent/moodys/PR_157551_426225moodys/PR_157551_426225htmlGlobal Credit Research Rating Action ## JUN #### Rating Action: Johnson & Johnson Moody's assigns Aaa to J&J's new sr. notes; stable outlook New York, June ##, #### -- Moody's Investors Service assigned a rating of Aaa to the new senior...6/19/2008 12:54:35 AMhtmlJohnson & JohnsonJohnson & Johnson426225150.0000NewsRating ActionPR_157551_426225Credit & Investment ResearchMoody's Global Credit Researchhttp://www.alacrastore.com/storecontent/newstex/PRN-0005-26074916newstex/PRN-0005-26074916xml Sweden, Jun. ##, #### (PRNewswire delivered by Newstex) -- Johnson & Johnson Nordic AB, a Johnson & Johnson company, today announced the acquisition of Amic, a privately held Swedish developer of in vitro diagnostic (IVD) technologies...0400000004016000040160050401600104016003040060000400600504002000040020066/18/2008 3:06:21 PM18000000180160001900000019003000PR Newswire USPRN-0005-26074916JOHNSON & JOHNSONJNJNewsNewstexhttp://www.alacrastore.com/storecontent/moodys/PBC_109473moodys/PBC_109473pdf...Following Moody s downgrades of several pharmaceutical competitors, Johnson & Johnson ( J&J ) remains the only Aaa-rated pharmaceutical company globally. J&J s exceptional market positions, excell ent revenue diversity, strong operating performance and conservative financial policies have remained key underpinnings to its Aaa credit rating. To date, thes e factors have buttressed J&J s Aaa rating from certain operating challenges includin g those related to the Cypher and Procrit franchises. Amidst a more challenging regulatory climate and increasing exposure to near- term patent expirations, continuation of J&J s stellar operating performance remains less certain. Combined with more aggressive share repurchases and potentially a larger acquis ition appetite, J&J s adh erence to Moody s Aaa guidelines could become tested. We believe that the event risk surrounded with additional acquisitions may be rising, but we at this time do not view this risk as substantial enough... 6/17/2008 12:38:56 PMpdfJohnson & JohnsonJohnson & Johnson426225300.0000AnalysisAnalysisPBC_109473Credit & Investment ResearchMoody's Global Credit ResearchUS - Veridex LLC, a unit of Johnson & Johnson Inc, definitively agreed to acquire bankrupt Immunicon Corp, a developer of diagnostic and research products, for $## mil in cash and the assumption of an undisclosed amount in liabilities. The transaction was subject to regulatory approval.6/13/2008 1:33:00 PM21100C45260A47816045260AVeridex LLCImmunicon CorpJohnson & Johnson IncImmunicon Corphttp://www.alacrastore.com/storecontent/Thomson_M%26A/Veridex_LLC_acquires_Immunicon_Corp-1985981020sdc/19859810201985981020Copyright © 2008, Thomson Financial, All Rights ReservedBusiness ServicesUnited StatesCommercial physical and biological research8731NJNew JerseySubsidiary2835:In vitro and in vivo diagnostic substances8731:Commercial physical and biological research2297:Nonwoven fabrics2676:Sanitary paper products2833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations2836:Biological products, except diagnostic substances2844:Perfumes, cosmetics, and other toilet preparations3841:Surgical and medical instruments and apparatus3843:Dental equipment and supplies3851:Ophthalmic goods5047:Medical, dental, and hospital equipment & supplies5048:Ophthalmic goods5122:Drugs, drug proprietaries, and druggists' sundries6719:Offices of holding companies, nec8731:Commercial physical and biological researchCravath, Swaine & MooreOTCBusiness ServicesUnited StatesCommercial physical and biological research8731PAPennsylvaniaPublicIMMC1022189001Mnfr,whl med equip,prodDvlp diagnostic,research prodCashLiabilitiesCommon Stock505131003Jun 13 20080.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000001.000002.000003.000004.000005.000006.000007.000008.000009.0000010.0000011.0000012.0000013.0000014.0000015.00000Veridex LLC, located inRaritan, New Jersey, developscancer diagnostic productsthat will enable earlierdisease detection as well asmonitoring and therapeuticselection. The company isinitially developing twoproduct lines: CellSearchassays that enumeratecirculating tumor cells inblood and GeneSearch assaysusing molecular technology.The company was founded in2004.Veridex LLC, located in Raritan, New Jersey, develops cancerdiagnostic products that will enable earlier diseasedetection as well as monitoring and therapeutic selection.The company is initially developing two product lines:CellSearch assays that enumerate circulating tumor cells inblood and GeneSearch assays using molecular technology. Thecompany was founded in 2004.Veridex LLC, located in Raritan, New Jersey, develops cancer diagnostic products that will enable earlier disease detection as well as monitoring and therapeutic selection. The company is initially developing two product lines: CellSearch assays that enumerate circulating tumor cells in blood and GeneSearch assays using molecular technology. The company was founded in 2004.1.000002.000003.000004.000005.000006.000007.000008.000009.0000010.0000011.0000012.0000013.0000014.0000015.0000016.0000017.00000Immunicon Corp, located inHuntingdon Valley,Pennsylvania, develops andcommercializes diagnostic andresearch products for cellanalysis and molecularresearch. Its instruments andreagents are used to capture,count and characterize rarecells including circulatingtumor cells (CTCs) in cancerpatients, circulatingendothelial cells (CECs),which are elevated in avariety of diseases, andprogenitor cells. The companywas founded in 1983.Immunicon Corp, located in Huntingdon Valley, Pennsylvania,develops and commercializes diagnostic and research productsfor cell analysis and molecular research. Its instrumentsand reagents are used to capture, count and characterizerare cells including circulating tumor cells (CTCs) incancer patients, circulating endothelial cells (CECs), whichare elevated in a variety of diseases, and progenitor cells.The company was founded in 1983.Immunicon Corp, located in Huntingdon Valley, Pennsylvania, develops and commercializes diagnostic and research products for cell analysis and molecular research. Its instruments and reagents are used to capture, count and characterize rare cells including circulating tumor cells (CTCs) in cancer patients, circulating endothelial cells (CECs), which are elevated in a variety of diseases, and progenitor cells. The company was founded in 1983.0.000000.000000.000000.00000NU.S. Dollar11 Jun 08Wed, 11 Jun 2008 00:00:00 ESTDate Announced: 06/11/2008Date Effective:Acq. of AssetsFriendly0.000000.000000.000000.000000.000000.00000Price/Share0.0000031 U.S. Dollar31.000000.0000031 U.S. Dollar31.000000.000000.000000.000000.0000031.0000031 U.S. Dollar1.00000N15.868000.000000.000000.000000.000000.0000031.0000031.000000.000000.000000.000000.000000.000000.000000.00000100.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.270000.240000.245000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000001.000002.000003.000004.000005.000006.000007.000008.000009.0000010.0000011.00000US - Veridex LLC, a unit ofJohnson & Johnson Inc,definitively agreed to acquirebankrupt Immunicon Corp, adeveloper of diagnostic andresearch products, for $31 milin cash and the assumption ofan undisclosed amount inliabilities. The transactionwas subject to regulatoryapproval.US - Veridex LLC, a unit of Johnson & Johnson Inc, definitively agreed to acquire bankrupt Immunicon Corp, a developer of diagnostic and research products, for $31 mil in cash and the assumption of an undisclosed amount in liabilities. The transaction was subject to regulatory approval.US - Veridex LLC, a unit of Johnson & Johnson Inc, definitively agreed to acquire bankruptImmunicon Corp, a developer of diagnostic and research products, for $31 mil in cash andthe assumption of an undisclosed amount in liabilities. The transaction was subject toregulatory approval.US - Veridex LLC, a unit of Johnson & Johnson Inc, definitively agreed to acquire bankrupt Immunicon Corp, a developer of diagnostic and research products, for $31 mil in cash and the assumption of anundisclosed amount in liabilities. The transaction was subject to regulatory approval.US - Veridex LLC, a unit of Johnson & Johnson Inc, definitively agreed to acquire bankrupt Immunicon Corp, a developer of diagnostic andresearch products, for $31 mil in cash and the assumption of an undisclosed amount in liabilities. The transaction was subject toregulatory approval.Pending0.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.00000Status:Pending-999.00000np0.00000-999.00000np0.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000002835:In vitro and in vivo diagnostic substances3826:Laboratory analytical instruments8731:Commercial physical and biological research3275001New YorkUnited States2834New JerseyPublicJNJ2835:In vitro and in vivo diagnostic substances3826:Laboratory analytical instruments8731:Commercial physical and biological research505131003OTCUnited States8731PennsylvaniaPublicIMMC31.0000031.0000031.0000015.86800Deal InformationThomson Financial Mergers & Acquisitionshttp://www.alacrastore.com/storecontent/ccbn/T1872591ccbn/T1872591norm... - Goldman Sachs - AnalystI am going to keep the intro short here since we are running a little bit behind on time. We are extremely delighted to have with us today Johnson & Johnson. This is a company that is one that just consistently executes across its broad portfolio of businesses.The Company has been extremely impressive in managing some challenging situations here, particularly on the pharma side as it has faced generic competition to some of its larger franchises. Yet the Company continues to have a very disciplined approach to the growth and to returning cash to shareholders. Really to talk about the pharma side of the business and J&J on a broader perspective, we have with us today Chris Poon. Chris is the Vice Chairman, Board of Directors, and Worldwide Chairman, Pharmaceuticals. We also have Louise Mehrotra, who is the Vice President of Investor Relations. So with that, let me turn it over to Chris. ... 6/12/2008 5:10:00 PMJohnson & Johnson54.0000FinalJohnson & Johnson at Goldman Sachs Healthcare Conference TranscriptJNJ9:20am PTTranscriptT1872591Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/newstex/PRN-0005-25872854newstex/PRN-0005-25872854xml CHAPEL HILL, N.C., Jun. ##, #### (PRNewswire delivered by Newstex) -- Bio-Pharma executives are increasingly finding value in the research products and services offered by Best Practices, LLC and in particular in use of the on-demand...0400000004002000040020060700000007014000070140126/10/2008 2:07:36 AM180000001800200018016000PR Newswire USPRN-0005-25872854JOHNSON & JOHNSONPFIZER INCJNJPFENewsNewstexhttp://www.alacrastore.com/storecontent/fitch/388942_report_framefitch/388942_report_framepdfFitch Ratings is a leading global rating agency committed to providing the world's credit markets with independent, timely and prospective credit opinions. Built on a foundation of organic growth and strategic acquisitions, Fitch Ratings has grown rapidly during the past decade gaining market presence throughout the world and across all fixed income markets.Abbott LaboratoriesAmgen, Inc.AstraZeneca plcBristol-Myers Squibb CompanyEli Lilly & CompanyGlaxoSmithKline plcJohnson & JohnsonMerck & Company, Inc.Novartis AGPfizer Inc.Roche Deutschland Holding GmbHSanofi-Aventis S.A.Schering-Plough CorporationWyeth800917408036051680361372803614198036159280361630803624348041717980457972804579768045797980457983806562368071041080843884850944736/9/2008 10:05:00 AM0100000001030000010317000103170301040000275Special ReportABTAMGNAZNBMYGSKJNJLLYMRKNOVNPFESANSGPWYE388942_report_frameCredit & Investment ResearchFitchResearchhttp://www.alacrastore.com/storecontent/newstex/PZM-0001-25852749newstex/PZM-0001-25852749xml ROCKVILLE, Md., Jun. #, #### (June delivered by Newstex) -- Cytomedix, Inc. (AMEX:GTF) today announced that Kshitij Mohan, Ph.D. will step down as Chairman and CEO effective June ##, ####, but will continue as a consultant to the Company....0900000009015000040000000400200004002001040160000401600804006000040060051300000013002000130020056/9/2008 8:06:14 AM1800000018020000180070001900000019001000PrimeNewswirePZM-0001-25852749CYTOMEDIX INCJOHNSON & JOHNSONSMITH & NEPHEW PLCJames NULL BensonKSHITIJ NULL MOHANMARTIN P ROSENDALEGTFJNJSNNNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/BW-0001-25794731newstex/BW-0001-25794731xml Jun. #, #### (Business Wire) -- Noven Pharmaceuticals, Inc. (NASDAQ:NOVN) today announced the results of its #### Annual Meeting of Stockholders. At the meeting held earlier today, stockholders elected the following persons to Novena€™s...090000000901500004000000040020000400200604016000040160080401600207000000070140000701401207003000070030011300000013010000130100056/5/2008 6:07:06 PM180000001800700018012000Business WireBW-0001-25794731JOHNSON & JOHNSONLILLY ELI & CONOVEN PHARMACEUTICALS INCDONALD A DENKHAUSJOHN G CLARKSONPEDRO P GRANADILLOPeter C BrandtROBERT G SAVAGESIDNEY BRAGINSKYWAYNE P YETTERJNJLLYNOVNNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/PRN-0005-25781583newstex/PRN-0005-25781583xml NEW BRUNSWICK, N.J., Jun. #, #### (PRNewswire-FirstCall delivered by Newstex) -- Johnson & Johnson is reviewing its Medical Devices & Diagnostics and Consumer businesses at a meeting with the investment community today, focusing on...0700000007005000130000001301000007014000070140180701401207014014070110000701100307015000070150030400000004002000040020060400600004006005040160000401600104016003130010001300100213002000130020056/5/2008 10:06:13 AM18000000180200001800200018018000190000001900200019002004PR Newswire USPRN-0005-25781583JOHNSON & JOHNSONCOLLEEN A GOGGINSJNJNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/CCN-0001-25725964newstex/CCN-0001-25725964xml MONTREAL, Jun. #, #### (Marketwire delivered by Newstex) -- TOPIGEN Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company specialized in developing products for respiratory disorders, today announced the appointment of Jeremy...0900000009015000070000000700500004000000040020000400200604016000040160080700300007003001070140000701401213000000130100001301000513002000130020056/3/2008 1:07:00 PM180000001800700019000000190020001900200719002012Marketwire CanadaCCN-0001-25725964JOHNSON & JOHNSONOSTEOLOGIX INC.SILENCE THERAPEUTICS PLCTARGETED GENETICS CORPJEREMY CURNOCK COOKJNJOLGXSLNCFTGENNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/PRN-0005-25679985newstex/PRN-0005-25679985xml SAN DIEGO, Jun. #, #### (PRNewswire delivered by Newstex) -- Trius Therapeutics, Inc. today announced the appointment of Paul Truex to its Board of Directors. Truex is the founder, President and CEO of Anthera Pharmaceuticals. PreviouslyA‚...090000000901500007000000070050000400000004002000040020060401600004016008070140000701401207003000070030016/2/2008 2:05:51 AM1800000018007000PR Newswire USPRN-0005-25679985JOHNSON & JOHNSONLILLY ELI & COPFIZER INCJNJLLYPFENewsNewstexhttp://www.alacrastore.com/storecontent/newstex/PRN-0005-25651997newstex/PRN-0005-25651997xml May ##, #### (PR Newswire delivered by Newstex) -- CHAPEL HILL, N.C., May ## /PRNewswire/ -- Given the increasing challenges to patent protection and new product approvals, pharmaceutical companies continue to seek external opportunities...040000000400200004002006040160000401600507000000070140000701401207003000070030010200000002002000020020065/30/2008 2:06:32 PM180000001801600018002000PR Newswire USPRN-0005-25651997JOHNSON & JOHNSONPFIZER INCJNJPFENewsNewstex